Acta Scientific Nutritional Health (ASNH)(ISSN: 2582-1423)

Mini Review Volume 6 Issue 12

An Update on Role of Curcumin in Colorectal Cancer-A Minireview

Kulvinder Kaur*, Gautam NK Allahbadia

Scientific Director, Ex-Rotunda-A Centre for Human Reproduction, Mumbai, India Antioquia, Antioquia

*Corresponding Author: Kulvinder Kaur, Scientific Director, Ex-Rotunda-A Centre for Human Reproduction, Mumbai, India.

Received: October 25, 2022; Published: November 18, 2022


Earlier we had reviewed the part of curcumin as an anti-oxidant, anti-inflammatory, neuro shielding, anticancer, hapatoprotecting, as well as cardio shielding actions. Further its bioavailability issues, bio effectiveness as well as safety parameters along with quality properties of Curcumin were further tackled, besides its role in PCOS. Here we tried to concentrate on the part of curcumin in Colorectal cancer (CRC). Diffusion of curcumin takes place via the cell membrane into the cell membrane endoplasmic reticulum (ER), mitochondria along with nucleus where its anti-oxidant characteristics get impacted. Hence its utilization has been recommended regarding chemopreventive, antimetastatic along with anti-angiogenic uses. Thus we conducted a minireview review on role on CRC with the utilization of search engines like PubMed, google scholar, web of science, Cochrane library from 1995 till date in 2022 with the utilization of MeSH terms like Curcumin; antioxidant actions; other anti-inflammatory actions; anti angiogenic actions; CRC; chemopreventive actions; ER stress; familial adenomatous polyposis (FAP); in vivo studies in animal models; in vitro studies. We found 2500 articles but selected only 53 articles for this review with the journals constraints of upto 50 references. No meta-analysis was done. In vitro studies conducted on human colon cancer cell lines illustrated that Curcumin hampered growth via cell cycle arrest at the G2/M along with G1 phase, besides crosstalk with numerous molecular targets. In vivo studies were conducted in mice having inflammatory along with genetic CRC in animal models possessing a chemopreventive action. regarding enhancement of bioavailability, it has been correlated with small particles that escalate its absorption on oral delivery with great outcomes in both inflammation as well as carcinogenesis. Furthermore curcumin utilization has been done in dietary formulation for CRC chemoprevention. These illustrated that in vitro along with in vitro anti carcinogenic characteristics in inflammatory along with genetic CRC.A synergestic action was pointed on utilization of unique dosages of the component that was lesser in contrast to experimentally utilized for single component. Thus with favourable actions in animal models, good scope of their working in humans preclinical studies.

Keywords: Curcumin; CRC; Animal Models; Apoptosis; Cellular Culture


  1. Shehzad A., et al. “Curcumin in cancer chemoprevention: molecular targets, Pharmacokinetics, bioavailability and Clinical trials”. Archiv der Pharmazie 343 (2010): 489-99.
  2. Chattopadhyay I., et al. “Turmeric and Curcumin: biological actions and medicinal applications”. Current Science 87 (2003): 44-53.
  3. Jaruga E., et al. “Apoptosis- independent alterations in membrane dynamics induced by Curcumin”. Experimental Cell Research 245 (1998): 303-312.
  4. Aggarwal BB and Sung B. “Pharmacologic basis for the role of curcumin in chronic diseases: an age-old spice with modern targets”. Trends in Pharmacological Sciences 30 (2009): 85-94.
  5. Fitzmaurice C., et al. “Global, Regional and cancer incidence, mortality, years of life lost, years lived with disability and disability adjusted years for32 cancer groups 1990-2015: a systematic analysis for the burden of disease study”. JAMA Oncology 3 (2017): 524-548.
  6. Castello A., et al. “Low adherence to the Western and high adherence to the Mediterranean dietary patterns could prevent Colorectal cancer”. European Journal of Nutrition 58 (2019): 1495-1505.
  7. Alexander DD., et al. “Red meat and Colorectal cancer: a quantitative update on the state of epidemiological science”. Journal of the American College of Nutrition 34 (2015): 521-543.
  8. Lopez-Lazaro M. “Anticancer and carcinogenic properties of curcumin: considerations for its Clinical development as a cancer chemopreventive and chemotherapeutic agent”. Molecular Nutrition and Food Research 52 (2008): S103-S127.
  9. Ismail NL., et al. “Mechanism of apoptosis induced by curcumin in Colorectal cancer”. International Journal of Molecular Sciences 20 (2019): 2454.
  10. Su P., et al. “Curcumin attenuates resistance to irinotecan via induction of apoptosis of cancer stem cells in chemo resistant colon cancer cells”. International Journal of Oncology 53 (2018): 1343-1353.
  11. Moseniak G., et al. “Curcumin induces permanent growth arrest of human Colon cancer cells: link between Senescence and autophagy”. Mechanisms of Ageing and Development 133 (2012): 444-455.
  12. Lim TG., et al. “Curcumin suppresses proliferation of Colon cancer cells by targeting CDK2”. Cancer Prevention Research 7 (2014): 466-474.
  13. Hernando E., et al. “Rb inactivation promote S genomic instability by uncoupling cell cycle progression from mitotic control”. Nature 430 (2004): 797-802.
  14. Kim KC and Lee CH. “Curcumin induces downregulation of E2F4 expression and apoptotic cell death in HCT-16 human Colon cancer cells, involvement of Reactive oxygen species”. The Korean Journal of Physiology and Pharmacology 14 (2010): 391-397.
  15. Watson JL., et al. “Curcumin causes superoxide anion production and p53 mediated apoptosisin human Colon cancer cells”. Cancer Letters 297 (2010): 1-8.
  16. Yin TF., et al. “Research progress on chemopreventive effects of phytochemicals on Colorectal cancer and their mechanisms”. World Journal of Gastroenterology 22 (2016): 7058-7068.
  17. Lee YK., et al. “Regulatory effect of the AMPK- COX-2 signaling pathway in Curcumin induced apoptosis in human HT29 Colon cancer cells”. Annals of the New York Academy of Sciences 1171 (2009): 489-494.
  18. Naugler WE. “NFκ Band cancer identifying targets and mechanisms”. Current Opinion in Genetics and Development 18 (2018): 19-26.
  19. Collect GP and Campbell FC. “Over expression of p65/RelA potentiates curcumin induced apoptosisin HCT-16 human Colon cancer cells”. Carcinogenesis 27 (2006): 1285-1291.
  20. Narayan S. “Curcumin, a multifunctional chemopreventive agent blocks growth of Colon cancer cells by targeting β-catenin mediated transactivation and cell to cell adhesion pathways”. Journal of Molecular Histology 35 (2004): 301-307.
  21. , et al. “The inhibitory mechanism of curcumin and its derivatives against the β-catenin/Tcf signaling”. FEBBS Letters 579 (2005): 2965-2971.
  22. Song G., et al. “Curcumin induces HT29 Colon adenocarcinoma cell apoptosis by activating p53 and regulating apoptosis -related protein expression”. Brazilian Journal of Medical and Biological Research 38 (2005): 1791-1798.
  23. Cao AL., et al. “Curcumin induces apoptosis in human gastric carcinoma AGS cells and Colon carcinoma HT29 cells through mitochondrial dysfunction and) endoplasmic reticulum stress”. Apoptosis 18 (2013): 1391-1402.
  24. , et al. “Chemopreventive efficacy and Pharmacokinetics of curcumin in min/+ mouse a model of familial adenomatous polyposis”. Cancer Epidemiology, Biomarkers and Prevention 11 (2002): 535-540.
  25. Park J and Contease CN. “Anticarcinogenic properties of curcumin on Colorectal cancer”. World Journal of Gastrointestinal Oncology 2 (20200): 169-176.
  26. McFaden RM., et al. “The role of curcumin in modulating Colonic microbiota during Colitis and Colon cancer prevention”. Inflammatory Bowel Diseases 21 (2015): 2483-2494.
  27. Guo Y., et al. “DNA methylome and transcriptome alterations and cancer prevention in Colitis accelerated Colon cancer in mice”. Carcinogenesis 39 (2018): 669-680.
  28. Han X., et al. “Orally deliverable nanotherapeutics for synergistic treatment of Colitis associated Colon cancer”. Theranostics 9 (2019): 7458-7473.
  29. Pricci M., et al. “Curcumin in Colorectal cancer: from basic to Clinical Evidence”. International Journal of Molecular Sciences 21 (2020): 2364.
  30. DiLeo A., et al. “ER-beta expression in large bowel adenomas: implications in Colon carcinogenesis”. Digestive and Liver Disease 40 (2008): 260-266.
  31. Girardi B., et al. “Chemoprevention of particular inflammation-related Colorectal cancer by Silymarin, acetyl-11 keto -beta- boswellic acid, Curcumin and maltodestrinenriched dietetic formulation in animal model”. Carcinogenesis 39 (2018): 1274-1282.
  32. , et al. “Epithelial turnover in duodenal familial adenomatous polyposis: a possible role for estrogen receptors?” World Journal of Gastroenterology 22 (2016): 3202-3211.
  33. Wang R., et al. “The comparative study of particular acetyl-11 keto -beta- boswellic acid (AKBA) and aspirin in the prevention of intestinal adenomatous polyposis in ApcMin/+mice”. Drug Discovery and Therapeutics 8 (2014): 25-32.
  34. Storka A., et al. “Safety, to lerability and Pharmacokinetics of liposomal curcumin in healthy humans”. International Journal of Clinical Pharmacology and Therapeutics 53 (2015): 54-65.
  35. Irving GR., et al. “Prolonged biologically active Colonic tissue levels of curcumin achieved after oral administration -a clinical pilot study including assessment of patient acceptability”. Cancer Prevention Research (Phila) 6 (2013): 119-128.
  36. Cruz-CorreaM., et al. “Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis”. Clinical Gastroenterology and Hepatology 4 (2006): 1035-1038.
  37. Cruz-CorreaM., et al. “Efficacy and Safety of curcumin in treatment of adenomas in patients with familial adenomatous polyposis”. Gastroenterology 155 (2018): 668-673.
  38. Alfonso-MorenoV., et al. “Chemoprevention of polyp recurrence by curcumin followed by silibinin in a case of multiple colorectal adenomas”. Revista Espanola de Enfermedades Digestivas 109 (2017): 875.
  39. Howells LM., et al. “Curcumin combined with FOLFOX chemotherapy is Safe and tolerable in patients with metastatic Colorectal cancer in a randomized phase IIatrial”. The Journal of Nutrition 149 (2019): 1133-1139.
  40. Irving GR., et al. “Combining curcumin (C3 complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable Colorectal cancer (CUFOX): study protocol for a randomized control trial”. Trials 16 (2015): 110.
  41. Griel R., et al. “A phase I dose escalation study on the Safety, tolerability and activity of liposomal curcumin (LipocurcTM) in patients with locally advanced or metastatic cancer”. Cancer Chemotherapy and Pharmacology 82 (2018): 695-706.
  42. Rehmani S., et al. “Treatment of Non-alcoholic fatty liver disease with curcumin: randomized placebo-controlled trial”. Phytotherapy Research 30 (2016): 1540-1548.
  43. Amin F., et al. “Clinical efficacy of the co administration of turmeric and black seeds (Kalongi)in Metabolic Syndrome-a double blind randomized control trial-TAK-MetS trial”. Complementary Therapies in Medicine 23 (2015): 165-174.
  44. Cheungsamarn S., et al. “Reduction of atherogenic risk in patients with type2 Diabetes by curcuminoid extract: a randomized control trial”. The Journal of Nutritional Biochemistry 25 (2014): 144-150.
  45. Maithli Kapaga Selvi N., et al. “Efficacy of curcumin as adjuvant therapy in type2 Diabetic patients”. Indian Journal of Clinical Biochemistry 30 (2015): 180-186.
  46. Medina-Caliz., et al. “Herbal and dietary supplement iinduced liver injuries in the Spanish DILI registry”. Clinical Gastroenterology and Hepatology 16 (2018): 1495-1502.
  47. Imam Z., et al. “Liver injury attributed to a curcumin supplement”.
  48. Ding L., et al. “Emerging prospects for the study of Colorectal cancer stem cells using human CRC patients derived organoids”. Current Cancer Drug Targets 3 (2022): 195-208.
  49. Oio A., et al. “Anti-cancer properties of curcumin in Colorectal cancer: a review”. Frontiers in Oncology 22 (2022): 181641.
  50. Kulvinder Kochar Kaur., et al. “A Plethora of Actions of Curcumin - A Magical Agent for Treatment of Wide Range of Diseases Varying FRO Neuroinflammatory Disease (AD, PD)-IBD to DM and CVD, NAFLD, NASH Along with Various Cancers - A Systematic Review". Acta Scientific Ophthalmology2 (2022): 1-11.
  51. Kulvinder Kochar Kaur., et al. “Therapeutic role of Curcumin on Glycemic Regulation, Lipid Parameters and potential benefits on hyperandrogenemia-A Short Communication”. Acta Scientific Nutritional Health 2 (2022): 1-4.


Citation: Kulvinder Kaur., et al. “An Update on Role of Curcumin in Colorectal Cancer-A Minireview". Acta Scientific Nutritional Health 6.12 (2022): 88-99.


Copyright: © 2022 Kulvinder Kaur., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.316

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 10, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US